A detailed history of Wambolt & Associates, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Wambolt & Associates, LLC holds 28,495 shares of ABBV stock, worth $5.75 Million. This represents 1.43% of its overall portfolio holdings.

Number of Shares
28,495
Previous 27,547 3.44%
Holding current value
$5.75 Million
Previous $5.02 Million 2.57%
% of portfolio
1.43%
Previous 1.51%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$154.79 - $180.76 $146,740 - $171,360
948 Added 3.44%
28,495 $4.89 Million
Q1 2024

Apr 30, 2024

BUY
$159.82 - $182.1 $15,502 - $17,663
97 Added 0.35%
27,547 $5.02 Million
Q4 2023

Feb 07, 2024

BUY
$137.6 - $154.97 $54,627 - $61,523
397 Added 1.47%
27,450 $4.25 Million
Q3 2023

Nov 06, 2023

BUY
$133.59 - $154.65 $85,497 - $98,976
640 Added 2.42%
27,053 $4.03 Million
Q2 2023

Aug 02, 2023

SELL
$132.51 - $164.9 $6,625 - $8,245
-50 Reduced 0.19%
26,413 $3.56 Million
Q1 2023

May 05, 2023

BUY
$144.61 - $166.54 $83,729 - $96,426
579 Added 2.24%
26,463 $4.22 Million
Q4 2022

Jan 31, 2023

BUY
$138.31 - $165.87 $53,387 - $64,025
386 Added 1.51%
25,884 $4.19 Million
Q3 2022

Oct 18, 2022

BUY
$134.21 - $153.93 $13,018 - $14,931
97 Added 0.38%
25,498 $3.42 Million
Q2 2022

Aug 01, 2022

BUY
$137.62 - $174.96 $102,114 - $129,820
742 Added 3.01%
25,401 $3.89 Million
Q1 2022

May 10, 2022

BUY
$131.98 - $163.75 $200,873 - $249,227
1,522 Added 6.58%
24,659 $4.01 Million
Q4 2021

Feb 08, 2022

BUY
$107.43 - $135.93 $115,379 - $145,988
1,074 Added 4.87%
23,137 $3.13 Million
Q3 2021

Oct 20, 2021

BUY
$106.4 - $120.78 $218,652 - $248,202
2,055 Added 10.27%
22,063 $2.41 Million
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $246,822 - $274,974
2,346 Added 13.28%
20,008 $2.29 Million
Q1 2021

Apr 19, 2021

BUY
$102.3 - $112.62 $275,903 - $303,736
2,697 Added 18.02%
17,662 $1.92 Million
Q4 2020

Jan 19, 2021

BUY
$80.49 - $108.67 $176,595 - $238,421
2,194 Added 17.18%
14,965 $1.6 Million
Q3 2020

Nov 04, 2020

BUY
$85.91 - $100.83 $229,293 - $269,115
2,669 Added 26.42%
12,771 $1.12 Million
Q2 2020

Jul 23, 2020

BUY
$73.37 - $98.18 $136,468 - $182,614
1,860 Added 22.57%
10,102 $992,000
Q1 2020

May 11, 2020

BUY
$64.5 - $97.79 $165,507 - $250,929
2,566 Added 45.21%
8,242 $628,000
Q4 2019

Feb 10, 2020

SELL
$72.13 - $90.25 $144 - $180
-2 Reduced 0.04%
5,676 $503,000
Q3 2019

Oct 15, 2019

SELL
$62.98 - $75.72 $14,170 - $17,037
-225 Reduced 3.81%
5,678 $430,000
Q2 2019

Jul 26, 2019

BUY
$65.7 - $83.98 $60,246 - $77,009
917 Added 18.39%
5,903 $429,000
Q1 2019

Apr 11, 2019

SELL
$77.14 - $90.79 $11,031 - $12,982
-143 Reduced 2.79%
4,986 $412,000
Q4 2018

Jan 29, 2019

BUY
$77.85 - $96.01 $399,292 - $492,435
5,129 New
5,129 $473,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $357B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Wambolt & Associates, LLC Portfolio

Follow Wambolt & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wambolt & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wambolt & Associates, LLC with notifications on news.